• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[氢化可的松经腰给药在广泛性乳腺癌患者综合治疗中的应用]

[Endolumbar administration of hydrocortisone in the complex treatment of patients with generalized breast cancer].

作者信息

Pankov A K, Mindlin S S, Verkhovtseva A I

出版信息

Vopr Onkol. 1975;21(5):99-104.

PMID:1243210
Abstract

An efficacy of the method of hormonal therapy--endolumbar hydrocortisone injection in patients with advanced breast cancer has been studied. A remission was gained in 28 of 41 patients. The method proved to be mostly effective in metastases in bones. Changes in the level of estrogens, 17-KS and 17-OCS excretion with the urine during the treatment indicate an endocrinous mechanism of this therapeutic effect. An efficacy of the method in extensive dissemination of the process, its relative simplicity and availability along with the absence of serious complications enabled the authors to hope that the suggested method may be widely used in practice.

摘要

对激素疗法——腰椎内注射氢化可的松治疗晚期乳腺癌患者的疗效进行了研究。41例患者中有28例获得缓解。该方法被证明对骨转移最为有效。治疗期间尿液中雌激素、17-酮类固醇和17-生氧皮质类固醇排泄水平的变化表明了这种治疗效果的内分泌机制。该方法在疾病广泛播散时的疗效、相对简单性和可行性以及无严重并发症,使作者们希望所建议的方法能在实践中得到广泛应用。

相似文献

1
[Endolumbar administration of hydrocortisone in the complex treatment of patients with generalized breast cancer].[氢化可的松经腰给药在广泛性乳腺癌患者综合治疗中的应用]
Vopr Onkol. 1975;21(5):99-104.
2
[The mechanism of action of hydrocortisone administered by lumbar puncture in breast cancer].[腰椎穿刺注射氢化可的松治疗乳腺癌的作用机制]
Vopr Onkol. 1973;19(9):19-23.
3
[Glucuronic acid, glucuronyltransferase and estrogens in breast cancer and precancer].
Vopr Onkol. 1978;24(10):66-70.
4
[Urinary hydroxyproline excretion before and after hypophysectomy in patients with bone metastases from breast cancer].[乳腺癌骨转移患者垂体切除术前、后的尿羟脯氨酸排泄情况]
Ugeskr Laeger. 1968 Oct 17;130(42):1766-71.
5
[Low-dose aminoglutethimide (500 mg/day) and hydrocortisone (30 mg/day) in advanced cancer of breast].低剂量氨鲁米特(500毫克/天)和氢化可的松(30毫克/天)用于晚期乳腺癌治疗
Bull Cancer. 1987;74(3):241-7.
6
[Aminoglutethimide therapy in advanced breast cancer].
Wien Med Wochenschr. 1985 Dec 31;135(23-24):608-11.
7
[The relationship between the course of mammary gland cancer and age and hormonal features of the body].[乳腺癌病程与年龄及机体激素特征之间的关系]
Vopr Onkol. 1969;15(5):73-7.
8
[Urinary hydroxyproline in advanced breast carcinoma and response to treatment with medroxyprogesterone acetate (MAP) in high doses].[晚期乳腺癌患者尿羟脯氨酸水平及大剂量醋酸甲羟孕酮(MAP)治疗反应]
Minerva Med. 1980 Sep 1;71(31):2215-9.
9
[Criteria for evaluating the efficacy of treatment of breast cancer metastases to the bones].[评估乳腺癌骨转移治疗疗效的标准]
Med Radiol (Mosk). 1986 Feb;31(2):28-31.
10
[Early results of hormonal treatment of advanced breast cancer with aminoglutethimide].[氨鲁米特对晚期乳腺癌进行激素治疗的早期结果]
Pol Tyg Lek. 1988 Aug 15;43(33):1057-9.